HIMS Slides Further as Options Hedging Hits New Extremes

The Street reaction to Q2 earnings, reported August 10, was mixed in direction but broadly constructive on targets. Morgan Stanley raised its target from $21 to $28 while holding Equal-Weight. Bank of America lifted from $30 to $32, also staying Neutral. TD Cowen moved from $25 to $30, likewise a Hold. Citigroup was the outlier — it lowered its target from $35 to $33 this week, keeping Neutral. The net result is a consensus of twelve Hold ratings, zero Underperforms, with a mean target somewhere in the high $20s to low $30s — broadly in line with where the stock traded a week ago, now looking slightly above the current price. The bull case centres on the Novo partnership bringing FDA-approved GLP-1 medications into the platform and a path to $1 billion in revenue. Bears point to slowing revenue growth, margin pressure from the shift toward branded drugs, and ongoing regulatory risk around compounding pharmacies. Factor scores add texture: the analyst recommendation differential ranks in the 93rd percentile, meaning the Street is still relatively constructive versus history, but the EPS surprise score sits in just the 2nd percentile — the company has a recent track record of missing estimates, and the short score rank is in the bottom 5th percentile of the universe.

On the institutional side, one detail is worth flagging. The CFO sold roughly $1 million of stock on August 14, alongside CEO Andrew Dudum selling $2.2 million and the COO trimming $1.3 million — all on the same day, largely through award-related sell transactions. Net insider activity over 90 days is actually positive at roughly $14.7 million, but those disposals sitting alongside a weakening tape will attract attention. BlackRock is the largest external holder at 12.3% of shares, having added 2.4 million shares as recently as July 31. Fidelity added a material 4.2 million shares in the same reporting period, suggesting at least some institutional buyers were active near higher prices.

The earnings reaction history is relevant here. The Q2 print on August 10 produced a 3.4% one-day decline and a 9.4% five-day loss — a pattern now playing out in the price. The next event is not until November 2. Between now and then, the key watch items are whether the put/call ratio normalises from its current extreme, whether availability continues to oscillate or tightens toward the lower end of its recent range, and whether the Street — having raised targets on the back of the Novo partnership narrative — begins to revisit those levels if the stock continues to drift.